BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12704530)

  • 1. Innovative therapies in wound healing.
    Shen JT; Falanga V
    J Cutan Med Surg; 2003; 7(3):217-24. PubMed ID: 12704530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers.
    Curran MP; Plosker GL
    BioDrugs; 2002; 16(6):439-55. PubMed ID: 12463767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers.
    Zaulyanov L; Kirsner RS
    Clin Interv Aging; 2007; 2(1):93-8. PubMed ID: 18044080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective comparison of diabetic foot ulcer and venous stasis ulcer healing outcome between a dermal repair scaffold (PriMatrix) and a bilayered living cell therapy (Apligraf).
    Karr JC
    Adv Skin Wound Care; 2011 Mar; 24(3):119-25. PubMed ID: 21326023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.
    Langer A; Rogowski W
    BMC Health Serv Res; 2009 Jul; 9():115. PubMed ID: 19591680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of bioengineered skin substitutes on diabetic foot ulcer and venous leg ulcer outcomes.
    Barber C; Watt A; Pham C; Humphreys K; Penington A; Mutimer K; Edwards M; Maddern G
    J Wound Care; 2008 Dec; 17(12):517-27. PubMed ID: 19052516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost.
    Zelen CM; Serena TE; Gould L; Le L; Carter MJ; Keller J; Li WW
    Int Wound J; 2016 Apr; 13(2):272-82. PubMed ID: 26695998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of Apligraf in the treatment of diabetic foot ulcers.
    Dinh TL; Veves A
    Plast Reconstr Surg; 2006 Jun; 117(7 Suppl):152S-157S; discussion 158S-159S. PubMed ID: 16799383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue engineered skin: Apligraf, a bi-layered living skin equivalent.
    Trent JF; Kirsner RS
    Int J Clin Pract; 1998 Sep; 52(6):408-13. PubMed ID: 9894378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers.
    Zelen CM; Gould L; Serena TE; Carter MJ; Keller J; Li WW
    Int Wound J; 2015 Dec; 12(6):724-32. PubMed ID: 25424146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Best-practice algorithms for the use of a bilayered living cell therapy (Apligraf) in the treatment of lower-extremity ulcers.
    Cavorsi J; Vicari F; Wirthlin DJ; Ennis W; Kirsner R; O'Connell SM; Steinberg J; Falanga V
    Wound Repair Regen; 2006; 14(2):102-9. PubMed ID: 16630097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of living bilayered cell therapy (Apligraf) for heel ulcers.
    Karr J
    Adv Skin Wound Care; 2008 Jun; 21(6):270-4. PubMed ID: 18525250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: a pilot study.
    Hu S; Kirsner RS; Falanga V; Phillips T; Eaglstein WH
    Wound Repair Regen; 2006; 14(4):427-33. PubMed ID: 16939570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing.
    Brem H; Balledux J; Bloom T; Kerstein MD; Hollier L
    Arch Surg; 2000 Jun; 135(6):627-34. PubMed ID: 10843357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of Apligraf in acute wounds.
    Kirsner RS
    J Dermatol; 1998 Dec; 25(12):805-11. PubMed ID: 9990773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with the use of apligraf to heal complicated surgical and nonsurgical wounds in a private practice setting.
    Shealy FG; DeLoach ED
    Adv Skin Wound Care; 2006; 19(6):310-22. PubMed ID: 16885645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apligraf treatment of venous ulcers and other chronic wounds.
    Falanga V
    J Dermatol; 1998 Dec; 25(12):812-7. PubMed ID: 9990774
    [No Abstract]   [Full Text] [Related]  

  • 18. The FDA and designing clinical trials for chronic cutaneous ulcers.
    Maderal AD; Vivas AC; Eaglstein WH; Kirsner RS
    Semin Cell Dev Biol; 2012 Dec; 23(9):993-9. PubMed ID: 23063664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Trends in Therapeutic Algorithm of Chronic Wound Healers: Recent Advances in Drug Delivery Systems, Concepts-to-Clinical Application and Future Prospects.
    Shao M; Hussain Z; Thu HE; Khan S; de Matas M; Silkstone V; Qin HL; Bukhari SNA
    Crit Rev Ther Drug Carrier Syst; 2017; 34(5):387-452. PubMed ID: 29256838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cultured skin as a 'smart material' for healing wounds: experience in venous ulcers.
    Sabolinski ML; Alvarez O; Auletta M; Mulder G; Parenteau NL
    Biomaterials; 1996 Feb; 17(3):311-20. PubMed ID: 8745328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.